<DOC>
	<DOC>NCT01387815</DOC>
	<brief_summary>The current study will compare the real - life effectiveness of adalimumab to topical and traditional systemic agents in the management of psoriasis and its impact on the patient's quality of life and societal burden of illness.</brief_summary>
	<brief_title>Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Active moderate or severe Plaque PS according to the judgment of the treating physician. The treating physician has decided to change the current treatment or add additional treatments for any reason including but not limited to inadequate response, intolerance, suboptimal compliance or patient preference. Currently participating in another prospective study with similar objectives. Patient cannot or will not sign informed consent. Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of Plaque PS.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Topical Agents</keyword>
	<keyword>Observational</keyword>
	<keyword>Traditional Systemic Agents</keyword>
	<keyword>Prospective</keyword>
	<keyword>Comparative</keyword>
	<keyword>Effectiveness</keyword>
</DOC>